百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06160 百济神州

休市中 05-09 16:08:07

140.400

-0.300

-0.21%

最高143.200	最低139.300	成交量381.30万
今开140.700	昨收140.700	日振幅2.77%
总市值1,970亿	流通市值1,808亿	总股本14.03亿
成交额5.37亿	换手率0.30%	流通股本12.88亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06160","market":"HK","secType":"STK","nameCN":"百济神州","latestPrice":140.4,"timestamp":1746778087034,"preClose":140.7,"halted":0,"volume":3813041,"delay":0,"floatShares":1288000000,"shares":1403000000,"eps":-3.6644082299404923,"marketStatus":"休市中","change":-0.3,"latestTime":"05-09 16:08:07","open":140.7,"high":143.2,"low":139.3,"amount":537222491,"amplitude":0.027719,"askPrice":140.5,"askSize":5400,"bidPrice":140.4,"bidSize":11400,"shortable":3,"etf":0,"ttmEps":-2.2158998094200926,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1747013400000},"marketStatusCode":7,"adr":0,"listingDate":1533657600000,"exchange":"SEHK","adjPreClose":140.7,"openAndCloseTimeList":[[1746754200000,1746763200000],[1746766800000,1746777600000]],"volumeRatio":0.6488434647026105,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"百济神州","latestPrice":243.52,"timestamp":1746774000000,"preClose":238.4,"halted":0,"volume":1711100,"delay":0,"premium":"-46.34"}},"requestUrl":"/m/hq/s/06160","defaultTab":"news","newsList":[{"id":"2534106327","title":"百济神州05月09日遭主力抛售1088.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2534106327","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534106327?lang=zh_cn&edition=full","pubTime":"2025-05-09 16:15","pubTimestamp":1746778546,"startTime":"0","endTime":"0","summary":"05月09日, 百济神州股价跌0.21%，报收140.40元，成交金额5.4亿元，换手率0.30%，振幅2.77%，量比0.65。百济神州今日主力资金净流出1088.9万元，连续3日净流出，上一交易日主力净流出592.3万元。该股近5个交易日下跌11.14%，主力资金累计净流出6089.7万元；近20日主力资金累计净流入3.1亿元，其中净流入天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509180124a6d8ec02&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509180124a6d8ec02&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2328871848.SGD","LU0307460666.USD","BK1161","LU0588546209.SGD","LU1969619763.USD","BK1583","BK1588","BK1500","06160"],"gpt_icon":0},{"id":"2534125994","title":"浦银国际证券给予百济神州买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2534125994","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534125994?lang=zh_cn&edition=full","pubTime":"2025-05-09 14:54","pubTimestamp":1746773647,"startTime":"0","endTime":"0","summary":"浦银国际证券05月08日发布研报称，给予百济神州（688235.SH，最新价：244元）买入评级。评级理由主要包括：1）1Q25收入符合预期，提前实现季度GAAPOP盈利及净盈利略好于预期，公司维持全年指引不变；2）泽布替尼海外销售持续高速增长；3）毛利率符合预期，经营效率持续提升。风险提示：泽布替尼海外销售增速未如预期；核心研发管线临床/审批延误或数据不及预期等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202505093400575973.html","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505093400575973.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06160","ONC"],"gpt_icon":0},{"id":"2534714036","title":"【券商聚焦】招银国际维持百济神州美股买入评级 指其泽布替尼表现具韧性","url":"https://stock-news.laohu8.com/highlight/detail?id=2534714036","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534714036?lang=zh_cn&edition=full","pubTime":"2025-05-09 13:45","pubTimestamp":1746769505,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际研报指，百济神州 公布的1Q25产品收入为11.1亿美元，同比增长48%，环比下降1%。其中，泽布替尼实现销售收入7.92亿美元，同比增长62%，环比下降4%。该行指，百济神州在1Q25实现了自成立以来首次季度GAAP盈利，为公司发展的重要里程碑。该行认为，百济神州的早期研发管线有望快速扩张。该行继续看好百济神州的收入增长前景及研发进展，维持目标价不变，为359.47美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509140510a6d8a66f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509140510a6d8a66f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160"],"gpt_icon":0},{"id":"2534011483","title":"2024年，医药生物板块人均薪酬高的10家企业揭晓","url":"https://stock-news.laohu8.com/highlight/detail?id=2534011483","media":"中国制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534011483?lang=zh_cn&edition=full","pubTime":"2025-05-09 10:29","pubTimestamp":1746757765,"startTime":"0","endTime":"0","summary":"截至目前，A股 医药生物 板块2024年年报披露已完毕，与此同时，药企员工人均薪酬情况也浮出水面。根据数据统计，2024年，医药生物板块人均薪酬高的十家企业分别是 百济神州 、 迪哲医药 、 亚虹医药 、 益方生物 、 福瑞股份 、 盟科药业 、 艾力斯 、 诺诚健华 、 天智航 、 君实生物 。2024年公司归属于上市公司股东的净亏损3.84亿元，亏损幅度有所减少。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509103820a4778552&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509103820a4778552&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["163118","06160","000808.SH","688192","BK0239"],"gpt_icon":0},{"id":"2534154571","title":"加拿大皇家银行：维持BeiGene(ONC.US)评级，由优于大市调整至优于大市评级, 目标价由312.00美元调整至311.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2534154571","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534154571?lang=zh_cn&edition=full","pubTime":"2025-05-09 01:12","pubTimestamp":1746724339,"startTime":"0","endTime":"0","summary":"加拿大皇家银行：维持BeiGene(ONC.US)评级，由优于大市调整至优于大市评级, 目标价由312.00美元调整至311.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/09011250242562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ONC","06160"],"gpt_icon":0},{"id":"2533535691","title":"百济神州一季度实现盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2533535691","media":"广州日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533535691?lang=zh_cn&edition=full","pubTime":"2025-05-08 23:40","pubTimestamp":1746718834,"startTime":"0","endTime":"0","summary":"百济神州港股、美股、A股三日前地同时发布的2025年第一季度财报透露的信息：公司总营收达到80.20亿元，同期相比增长了48.64%；利润总额比去年同期多了近20亿元，由亏转盈。公司在美国通用会计准则下，首次实现季度盈利。百济神州的核心产品泽布替尼、替雷利珠单抗的销售额暴涨。今年一季度，泽布替尼全球销售额达56.92亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505083399819516.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","LU0588546209.SGD","BK1588","LU0307460666.USD","BK1583","LU2328871848.SGD","06160","BK1161","ONC","LU1969619763.USD","BK1500"],"gpt_icon":0},{"id":"2533899751","title":"百济神州(ONC)盘前涨超2% 机构看好泽布替尼2Q25环比持续增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2533899751","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533899751?lang=zh_cn&edition=full","pubTime":"2025-05-08 19:44","pubTimestamp":1746704652,"startTime":"0","endTime":"0","summary":"金吾财讯 | 百济神州(ONC)盘前涨超2%，截至发稿，报236.96美元。消息面上，海通国际研报指出，1Q25百济神州实现归母净利润127万美元（1Q24亏损2.5亿美元)，首次实现单季度经常性业务盈利（US GAAP 口径）。管理层维持全年49-53亿美元收入指引不变。该行认为百济神州的业绩整体符合预期。海外收入增长拉动公司业绩扭亏。1Q25公司产品收入同比增长48.4%至11.1亿美元，主要得益于泽布替尼的海外销售增长。看好泽布替尼2Q25环比持续增长，泽布替尼距离销售峰值仍有较大空间。维持“优于大市”评级。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/N2NlYWIzMDQ5MjY5YzU0NWM0NDMwZTE4ZDQ3MjY3ODIxNTA5MDg=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/N2NlYWIzMDQ5MjY5YzU0NWM0NDMwZTE4ZDQ3MjY3ODIxNTA5MDg=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"288322","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","06160","LU1969619763.USD","BK1500","LU2328871848.SGD","LU0307460666.USD","BK1161","BK1588","BK1583","688235","BK0239","LU0588546209.SGD","BK4139"],"gpt_icon":0},{"id":"2533890882","title":"“扭亏”上岸，百济一季度营收80亿，新“一哥”诞生？","url":"https://stock-news.laohu8.com/highlight/detail?id=2533890882","media":"医药经济报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533890882?lang=zh_cn&edition=full","pubTime":"2025-05-08 17:34","pubTimestamp":1746696884,"startTime":"0","endTime":"0","summary":"2025年一季度，泽布替尼在美国销售额总计40.41亿元，同比增长61.9%。2024年年初，百济神州公布全年业绩情况，泽布替尼2023年全年全球销售额达13亿美元，成为“首个国产十亿美元分子”。然而，百济神州的泽布替尼仅用了短短四年时间，便跻身于“重磅炸弹”药物的行列，展现了其非凡的市场潜力和影响力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508174243a6d77556&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508174243a6d77556&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","ONC","06160"],"gpt_icon":0},{"id":"2533903643","title":"百济神州05月08日遭主力抛售592.3万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533903643","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533903643?lang=zh_cn&edition=full","pubTime":"2025-05-08 16:15","pubTimestamp":1746692129,"startTime":"0","endTime":"0","summary":"05月08日, 百济神州股价跌0.21%，报收140.70元，成交金额7.1亿元，换手率0.39%，振幅2.70%，量比0.92。百济神州今日主力资金净流出592.3万元，上一交易日主力净流出6761.9万元。该股近5个交易日下跌5.91%，主力资金累计净流出3111.2万元；近20日主力资金累计净流入3.4亿元，其中净流入天数为15日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508173353a4767c66&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508173353a4767c66&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1500","LU0588546209.SGD","BK1583","BK1161","06160","LU0307460666.USD","BK1588","LU1969619763.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2533592923","title":"研报掘金丨浦银国际：维持百济神州“优于大市”评级，目标价182.35港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533592923","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533592923?lang=zh_cn&edition=full","pubTime":"2025-05-08 14:02","pubTimestamp":1746684139,"startTime":"0","endTime":"0","summary":"浦银国际研报指出，1Q25百济神州(6160.HK)实现归母净利润127万美元（1Q24亏损2.5亿美元)，首次实现单季度经常性业务盈利（US GAAP 口径）。管理层维持全年49-53亿美元收入指引不变。该行认为百济神州的业绩整体符合预期。海外收入增长拉动公司业绩扭亏。1Q25公司产品收入同比增长48.4%至11.1亿美元，主要得益于泽布替尼的海外销售增长。看好泽布替尼2Q25 环比持续增长，泽布替尼距离销售峰值仍有较大空间。予目标价182.35元港币，维持“优于大市”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050814022494f01a15&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050814022494f01a15&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160"],"gpt_icon":0},{"id":"2533497099","title":"中国银河：首次覆盖百济神州给予买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2533497099","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533497099?lang=zh_cn&edition=full","pubTime":"2025-05-08 12:36","pubTimestamp":1746678983,"startTime":"0","endTime":"0","summary":"中国银河证券股份有限公司程培,闫晓松近期对百济神州进行研究并发布了研究报告《百济神州2024年年度报告业绩点评：海外放量超预期，创新管线迎来拐点》，首次覆盖百济神州给予买入评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050800014458.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688235","601881","06160"],"gpt_icon":0},{"id":"2533949165","title":"18年无一款商业化产品，现金流仅够撑半年，累亏15亿的瑞博生物受劲敌压制","url":"https://stock-news.laohu8.com/highlight/detail?id=2533949165","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533949165?lang=zh_cn&edition=full","pubTime":"2025-05-08 12:20","pubTimestamp":1746678050,"startTime":"0","endTime":"0","summary":"近日，专注于siRNA疗法的研究并开发小核酸药物的瑞博生物递表港交所，引发了市场对相关创新疗法的广泛探讨。作为备受市场关注的企业之一，瑞博生物当前却尚未有任何商业化的产品，创收主要依靠合作授权收取的费用。弗若斯特沙利文的数据显示，瑞博生物的核心产品RBD4059即靶向FXI的siRNA是全球首款、也是临床开发进展最快的用于治疗血栓性疾病的siRNA药物。从成立至今，累计亏损更是达到了15.22亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/256732","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU0588546209.SGD","LU1969619763.USD","06160","01477","BK1500","LU0307460666.USD","BK1161","BK1583","BK1191","BK1574","LU2328871848.SGD","BK1588"],"gpt_icon":1},{"id":"2533592300","title":"百济神州2025Q1：替雷利珠单抗销售额12亿元，同比增长19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2533592300","media":"生物药大时代","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533592300?lang=zh_cn&edition=full","pubTime":"2025-05-08 11:37","pubTimestamp":1746675469,"startTime":"0","endTime":"0","summary":"5月7日，百济神州发布2025Q1财报，2025年第一季度总收入为80.48亿元，同比增长50.2%，总收入的增长主要得益于百悦泽在美国和欧洲的销售额增长。其产品收入为79.85亿元，同比增长49.9%。血液肿瘤领域产品泽布替尼在第一季度实现全球销售额总计56.92亿元，同比增长63.7%。此外，百济神州透露预计将于2025 年下半年取得FDA和EC对泽布替尼片剂新剂型上市申请的批准。从安进公司获得授权许可的产品和百泽安的销售额为12.45亿元，同比增长19.3%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508142221a476447d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508142221a476447d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","688235","BK0239","06160"],"gpt_icon":0},{"id":"2533085920","title":"每日医刻｜司美格鲁肽一季度销量全球第一；百济神州 Q1：首次实现季度盈利！","url":"https://stock-news.laohu8.com/highlight/detail?id=2533085920","media":"财健道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533085920?lang=zh_cn&edition=full","pubTime":"2025-05-08 10:59","pubTimestamp":1746673165,"startTime":"0","endTime":"0","summary":"将“财健道”设为星标持续关注，不错过好看每日医刻1司美格鲁肽一季度销量全球第一5月7日，诺和诺德公布2025年一季度业绩，总营收780.87亿丹麦克朗，约112.16亿美元，同比增长18%。4百济神州 Q1：首次实现季度盈利5 月 7 日，百济神州发布 2025 年第一季度美股业绩报告及 A 股业绩快报，实现营收 80.48 亿元，同比增长 50.2%。财务表现方面，2025 年第一季度，百济神州凭借全球收入的快速增长和经营费用的有效管理，在盈利方面再次取得重大进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508155200a6d74f34&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508155200a6d74f34&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK0239","ONC","06160"],"gpt_icon":0},{"id":"2533917313","title":"百济神州：泽布替尼新剂型预计今年下半年在欧美获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2533917313","media":"医药魔方","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533917313?lang=zh_cn&edition=full","pubTime":"2025-05-08 10:35","pubTimestamp":1746671753,"startTime":"0","endTime":"0","summary":"目前泽布替尼获批的剂型为胶囊。百济神州已计划对R/R MCL适应症的II期临床试验进行数据读出并有望针对该项适应症在2025年下半年递交全球加速上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508105036a47617c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508105036a47617c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","LU2328871848.SGD","688235","LU1969619763.USD","ONC","LU0307460666.USD","LU0588546209.SGD","06160","BK1500","BK1583","BK1161"],"gpt_icon":0},{"id":"2533914871","title":"两大千亿营收巨头领跑！云南白药首破400亿，百济神州、恒瑞大涨，人福、片仔癀……创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2533914871","media":"米内网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533914871?lang=zh_cn&edition=full","pubTime":"2025-05-08 10:08","pubTimestamp":1746670080,"startTime":"0","endTime":"0","summary":"从营收增速来看，百济神州、新和成、恒瑞医药、华润三九等5家均有双位数增长；智飞生物跌幅最大，超过50%。上海医药、九州通两家千亿营收龙头继续领跑，重药控股、南京医药、国药股份均超过500亿元。创新高，云南白药首破400亿此外，人福医药、恒瑞医药、科伦药业、片仔癀等超20家创新高。其中，国药股份首次突破500亿元，云南白药首次突破400亿元，百济神州、新和成和鹭燕医药首次突破200亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050810152094efe52a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050810152094efe52a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["000538","ONC","06160","600276","688235","600436"],"gpt_icon":0},{"id":"2533198039","title":"【券商聚焦】海通国际维持百济神州(06160)“优于大市”评级 指其业绩整体符合预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2533198039","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533198039?lang=zh_cn&edition=full","pubTime":"2025-05-08 09:55","pubTimestamp":1746669314,"startTime":"0","endTime":"0","summary":"金吾财讯 | 海通国际发研指，1Q25百济神州 实现收入11.2亿美元，其中产品收入11.1亿美元。管理层维持全年49-53亿美元收入指引不变。该行认为百济神州的业绩整体符合预期。该行指，1Q25公司产品收入同比增长48.4%至11.1亿美元，主要得益于泽布替尼的海外销售增长。分产品来看：泽布替尼实现收入7.9亿美元。截至1Q25公司在手现金及现金等价物25.2亿美元。基于WACC9%，永续增长率4.0%（均不变），对应目标价182.35元港币，维持“优于大市”评级。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1958309","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","688235","06160"],"gpt_icon":0},{"id":"2533918950","title":"金十数据整理：每日港股市场要闻速递（5月8日 周四）","url":"https://stock-news.laohu8.com/highlight/detail?id=2533918950","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533918950?lang=zh_cn&edition=full","pubTime":"2025-05-08 09:13","pubTimestamp":1746666783,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["GELYY","BK1119","LU1497733557.USD","HSCEI","ONC","BK1227","LU1226287529.USD","06158","FXE","80175","LU0149721374.USD","LU2039709279.SGD","LU1497734951.SGD","LU0605514214.HKD","82020","LU0164880469.USD","LU0251143458.SGD","MEURmain","02020","600735","BK1610","80883","BK1539","EVS.SI","EURmain","LU0708995583.HKD","688235","IE00B031J352.USD","LU0516422952.EUR","BK1152","YANG","01541","03301","EUO","IE00BZ08YR35.GBP","LU1226287875.USD","LU0320764599.SGD","CHL","LU1064130708.USD","00175","00941","07226","01310","ANPDY","06160","600941","BK1578","HSTECH","00168","ZK"],"gpt_icon":0},{"id":"2533899923","title":"音频 | 格隆汇5.8盘前要点—港A美股你需要关注的大事都在这","url":"https://stock-news.laohu8.com/highlight/detail?id=2533899923","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533899923?lang=zh_cn&edition=full","pubTime":"2025-05-08 07:39","pubTimestamp":1746661157,"startTime":"0","endTime":"0","summary":"美联储再次暂停降息，美股反弹，谷歌大跌超7%，中概指数跌2.34%；特朗普政府拟取消AI芯片限制；振兴欧盟，默茨和马克龙誓言重启法德关系；日本米价再创新高；证监会明确！绩差基金经理薪酬应明显下降；中国人自己的电脑来了...","market":"sg","thumbnail":"https://img7.gelonghui.com/column/2/109.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/109.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/2142035","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1500","LU1969619763.USD","06160","BK1583","BK1161","LU0307460666.USD","LU2328871848.SGD","LU0588546209.SGD","BK1588"],"gpt_icon":0},{"id":"2533932462","title":"百济神州一季度亏损大幅收窄 国内BTK抑制剂销售加速、PD-1销售减速","url":"https://stock-news.laohu8.com/highlight/detail?id=2533932462","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533932462?lang=zh_cn&edition=full","pubTime":"2025-05-07 22:41","pubTimestamp":1746628873,"startTime":"0","endTime":"0","summary":"作为国内创新药龙头企业，百济神州目前有3款主要自研产品，分别为BTK抑制剂泽布替尼、PD-1单抗替雷利珠单抗和PARP抑制剂帕米帕利。对于一季度的产品收入增长，公司归因于百悦泽、百泽安及安进授权产品的销售增长。具体来说，今年第一季度，百悦泽全球销售额总计56.92亿元，同比增长63.7%。而在竞争更为激烈的国内PD-1单抗市场中，百泽安实现销售额12.45亿元，同比增长19.3%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050722420597521340&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050722420597521340&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","PD","BK4139","BK4023","LU1169589451.USD","LU1169590202.USD","06160","688235"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beigene.cn","stockEarnings":[{"period":"1week","weight":-0.0818},{"period":"1month","weight":0.0825},{"period":"3month","weight":0.0174},{"period":"6month","weight":0.1396},{"period":"1year","weight":0.4047},{"period":"ytd","weight":0.2857}],"compareEarnings":[{"period":"1week","weight":0.0161},{"period":"1month","weight":0.1285},{"period":"3month","weight":0.0821},{"period":"6month","weight":0.1032},{"period":"1year","weight":0.2336},{"period":"ytd","weight":0.14}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"BeiGene Ltd是一家全球生物技术公司，致力于为全球癌症患者发现和开发肿瘤治疗方法。该公司已发现并开发三种批准药物，包括BRUKINSA，一种布鲁顿酪氨酸激酶的小分子抑制剂，用于治疗各种血癌；TEVIMBRA（tislelizumab），一种抗PD-1抗体免疫疗法，用于治疗各种实体瘤和血癌；以及是聚ADP核糖聚合酶1(PARP1)和PARP2的选择性小分子抑制剂pamiparib。该公司已获得在美国、中华人民共和国（中国）、欧盟、英国、加拿大、澳大利亚和其他国际市场销售BRUKINSA，在欧盟和中国销售替雷利珠单抗，以及在中国销售帕米帕尼的批准。它还专注于在Amgen Inc独家授权下在中国商业化癌症药物，如XGEVA、BLINCYTO、KYPROLIS等。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.009815},{"month":2,"riseRate":0.571429,"avgChangeRate":0.046604},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.052519},{"month":4,"riseRate":0.428571,"avgChangeRate":0.037509},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.061841},{"month":6,"riseRate":0.5,"avgChangeRate":0.011188},{"month":7,"riseRate":0.833333,"avgChangeRate":0.075403},{"month":8,"riseRate":0.833333,"avgChangeRate":0.065797},{"month":9,"riseRate":0.428571,"avgChangeRate":0.01247},{"month":10,"riseRate":0.571429,"avgChangeRate":-0.017395},{"month":11,"riseRate":0.571429,"avgChangeRate":0.120457},{"month":12,"riseRate":0.142857,"avgChangeRate":-0.068807}],"exchange":"SEHK","name":"百济神州","nameEN":"BEIGENE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.4","shortVersion":"4.33.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(06160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,06160,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(06160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}